Shamrock Ind Peer Comparison

BSE: 531240

₹25.96

₹0.00 (0.00%)

As on 31-Aug-2026IST

Market cap

₹14 Cr

Revenue (TTM)

₹0 Cr

P/E Ratio

--

P/B Ratio

33.8

Div. Yield

0 %

Edit

	Shamrock Ind	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Market cap (₹ Cr)	14	35,248	29,407	17,416	15,153
Revenue (₹ Cr)	--	9,683	2,372	2,590	1,108
Net Profit (₹ Cr)	-1.07	1,018.97	497.77	603.02	270.18
Net Margin (%)	-4,119.23	10.47	20.72	22.63	23.29
RoE (%)	-127.05	21.30	28.49	19.61	14.45
Price to Earnings	--	34.85	59.08	28.88	55.03
Price-To-Book	33.78	6.74	14.55	5.00	7.31

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	Shamrock Ind	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Operating Revenue	0.00	9,683.45	2,371.81	2,590.40	1,108.39
Total Income	0.03	9,730.84	2,402.61	2,664.23	1,159.90
Total Expenditure	1.10	7,739.53	1,608.91	1,753.71	720.01
EBITDA	-1.10	1,943.92	762.90	836.69	388.38
Depreciation	0.00	425.10	98.11	78.88	74.78
EBIT	-1.10	1,518.82	664.79	757.81	313.60
Interest	0.00	148.45	26.33	5.43	0.26
Other Income	0.03	47.39	30.80	73.83	51.50
Exceptional Items	0.00	-27.85	0.00	-25.66	-3.28
Profit before Tax	-1.07	1,389.91	669.26	800.55	361.56
Provision for Tax	0.00	370.94	171.48	197.53	91.39
Profit after Tax	-1.07	1,018.97	497.77	603.02	270.18

Liabilities (₹ Cr)

	Shamrock Ind	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Shareholder's Funds	0.52	4,950.03	1,874.47	3,332.13	2,017.06
Minority Interest	0.00	-7.58	0.00	0.00	2.51
Non-Current Liabilities	0.00	723.57	345.47	142.73	50.51
Current Liabilities	1.15	3,912.24	710.20	508.04	169.08
Total Liabilities	1.64	8,121.73	2,179.88	3,753.59	2,034.25

Assets (₹ Cr)

	Shamrock Ind	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Non-Current Assets	0.00	3,392.16	1,290.62	1,321.38	957.22
Current Assets	1.66	5,612.10	1,483.13	2,649.36	1,250.11
Total Assets	1.64	8,121.73	2,179.88	3,753.59	2,034.25
Total Debt*	0.00	731.70	136.01	0.00	0.38
Net Current Assets	0.51	1,699.86	772.93	2,141.33	1,081.04
Contingent Liabilities	--	393.94	8.97	4.82	3.91

Cashflow (₹ Cr)

	Shamrock Ind	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Cash From Operating Activities	-0.13	851.71	317.40	391.52	244.52
Cash Flow from Investing Activities	-0.79	-94.00	-298.16	-615.65	-159.99
Cash from Financing Activities	--	-813.96	24.96	-6.23	-98.77
Net Cash Inflow / Outflow	-0.92	-56.25	44.21	-230.35	-14.24

Ratios

Profitability Ratios

	Shamrock Ind	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
ROCE (%)	-7.56	22.49	23.45	25.50	29.62
ROE (%)	-127.05	21.30	28.49	19.61	14.45
ROA (%)	-64.91	11.42	19.48	16.31	12.66
EBIT Margin (%)	--	15.68	28.03	29.25	28.29
Net Margin (%)	-4,119.23	10.47	20.72	22.63	23.29
Cash Profit Margin (%)	--	0.00	0.00	0.00	0.00

Growth Ratios

	Shamrock Ind	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Revenue Growth (%)	--	18.36	78.33	7.93	-6.72
EBIT Growth (%)	-483.51	30.43	303.07	19.88	-26.64
Net Profit Growth (%)	-469.68	32.39	182.61	21.66	-24.38
EPS Growth (%)	-469.68	36.68	277.72	25.42	-21.99
Book Value Growth (%)	-7.28	50.94	18.89	20.94	18.74

Valuation Ratios

	Shamrock Ind	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Price / Earnings	0.00	34.14	59.08	27.97	54.55
Price / Book Value	4.20	6.74	14.55	5.00	7.31
Dividend Yield (%)	0.00	0.19	0.15	0.35	0.52
EV/EBITDA	-53.31	18.68	38.34	19.88	37.95
Market Cap (₹ Cr)	--	20,327.45	15,494.53	13,228.83	17,537.35

Solvency Ratios

	Shamrock Ind	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Debt to Equity	0.00	0.05	0.09	0.00	0.00
Short term debt to equity ratio	--	0.11	--	--	0.00
Current Ratio	1.45	1.43	2.09	5.21	7.39
Quick Ratio	1.45	0.82	1.37	3.85	5.46
Interest Coverage	--	10.36	26.41	148.49	1,386.30

Operating Efficiency Ratios

	Shamrock Ind	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Debtors to sales (%)	--	26.46	22.82	41.42	41.52
Asset Turnover	0.00	1.09	0.93	0.70	0.52
Receivable days	--	87.83	85.17	132.12	132.49
Inventory Days	--	78.64	90.97	102.08	68.07
Payable days	--	174.97	137.94	133.54	123.94
Cash Conversion Cycle	--	-8.50	38.21	100.66	76.63

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly